|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
no
|
|
gptkbp:advertising
|
innovation-driven
|
|
gptkbp:budget
|
published
|
|
gptkbp:businessModel
|
partnerships
|
|
gptkbp:CEO
|
gptkb:Patrick_Amstutz
|
|
gptkbp:clinicalTrials
|
yes
ongoing
Phase II
Phase III
Phase I
conducted globally
|
|
gptkbp:collaborations
|
gptkb:University_of_Zurich
gptkb:ETH_Zurich
active
ongoing
|
|
gptkbp:community_engagement
|
active
|
|
gptkbp:employees
|
approximately 100
|
|
gptkbp:financialPerformance
|
monitored
reported quarterly
|
|
gptkbp:focus
|
therapeutics
|
|
gptkbp:founded
|
2004
|
|
gptkbp:funding
|
over $100 million
|
|
gptkbp:global_presence
|
yes
|
|
gptkbp:governance
|
established
|
|
gptkbp:headquarters
|
gptkb:Zurich,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Molecular Partners
|
|
gptkbp:investmentFocus
|
Venture capital
transparent
|
|
gptkbp:market
|
varies
biopharmaceuticals
|
|
gptkbp:partnerships
|
yes
Novartis
AbbVie
|
|
gptkbp:patentCitation
|
granted
|
|
gptkbp:platforms
|
DARPins technology
|
|
gptkbp:publications
|
numerous
|
|
gptkbp:regulatoryCompliance
|
in progress
|
|
gptkbp:relatedEvent
|
held annually
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
in development
infectious diseases
|
|
gptkbp:research_focus
|
protein engineering
|
|
gptkbp:social_responsibility
|
active
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
yes
|
|
gptkbp:supplyChain
|
MP0250
MP0274
|
|
gptkbp:supportRole
|
established
|
|
gptkbp:sustainability_initiatives
|
implemented
|
|
gptkbp:technology
|
DARPins
|
|
gptkbp:tributaryOf
|
infectious diseases
cancer therapies
|